BARDA and Partner Therapeutics foster a new partnership around their FDA-approved drug, Leukine® to improve patient care for sepsis patients

Lexington, MA – September 20, 2021 /PRNewswire/ — Partner Therapeutics, Inc. (PTx) announced a collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, and Labcorp Drug Development to advance a new diagnostic approach to select immunoparalyzed sepsis patients that could benefit most from Leukine (sargramostim).  Through advancement of a Laboratory Developed Test (LDT) for monocyte HLA-DR, Partner Therapeutics will be able to identify sepsis patients exhibiting an immune suppressed, or immunoparalyzed (IP) state and clinically evaluate Leukine as a study therapy in these individuals. The ability to identify patients with IP sepsis enables a precision medicine approach to maximize clinical benefit from immune boosting study therapy with Leukine.

Labcorp receives Emergency Use Authorization for at-home collection kit for combined COVID-19 and flu detection

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 1, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a combined home collection kit that detects COVID-19 and influenza A/B simultaneously in individuals as young as 2 years of age. The kit will be available at no upfront cost to those who meet clinical guidelines, which may include experiencing symptoms, being exposed to someone with COVID-19 or if asked to be tested by a health care provider.

Labcorp to announce third quarter financial results on October 28, 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 28, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the third quarter of 2021 before the market opens on Thursday, October 28, 2021 . The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website.

AWS shares new business momentum milestones and announces three new capabilities for Amazon Connect

SEATTLE, Wash., Sept. 27, 2021—Today at Enterprise Connect, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), shared new business momentum milestones and announced three new capabilities for Amazon Connect that improve contact center agent productivity and provide superior service by making customer interactions more effective, personal, and natural. AWS shared for the first time that tens of thousands of AWS customers are supporting more than 10 million contact center interactions a day on Amazon Connect, an easy-to-use, highly scalable, and cost-effective omnichannel cloud contact center solution. The new features announced today are designed to give agents the right information at the right time to answer customer questions faster, provide fast and secure caller authentication, and make communicating with customers easier and more efficient. To get started with Amazon Connect, visit aws.amazon.com/connect/.